Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome
- 31 October 1998
- journal article
- clinical trial
- Published by Elsevier in Journal of Hepatology
- Vol. 29 (4) , 565-570
- https://doi.org/10.1016/s0168-8278(98)80151-7
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansionHepatology, 1998
- Hepatorenal SyndromeSeminars in Liver Disease, 1997
- Hepatorenal syndromeDigestive Diseases and Sciences, 1996
- Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis†Hepatology, 1996
- Tealipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross-over study 1H pital Cantonal Universitaire, Geneva, Switzerland, 2INSERM U24, H pital Beaujon, Clichy, FranceHepatology, 1995
- Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascitesGastroenterology, 1993
- The role of atrial natriuretic peptide (ANP) in chronic liver diseasePharmacology & Therapeutics, 1993
- Creatinine clearance during cimetidine administration for measurement of glomerular filtration rateThe Lancet, 1992
- Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosisGastroenterology, 1991
- Potential Role of Increased Sympathetic Activity in Impaired Sodium and Water Excretion in CirrhosisNew England Journal of Medicine, 1982